Targeting the somatostatin receptor in pituitary and neuroendocrine tumors

By Veenstra Marije J   de Herder Wouter W   Feelders Richard A   Hofland Leo J  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 11, 2013-11 ,pp. : 1329-1343

Informa Healthcare

Access to resources Recommend Favorite

The somatostatin receptor subtype 5 in neuroendocrine tumours

By van der Hoek Joost   Lamberts Steven WJ   Hofland Leo J  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 3, 2010-03 ,pp. : 385-399

Informa Healthcare

Access to resources Recommend Favorite

Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog

By Dubey Nazneen   Varshney Raunak   Shukla Jaya   Ganeshpurkar Aditya   Hazari Puja P.   Bandopadhaya Guru P.   Mishra Anil K.   Trivedi Piyush  

Drug Delivery, Vol. 19, Iss. 3, 2012-04 ,pp. : 132-142

Informa Healthcare

Access to resources Recommend Favorite

Somatostatin antagonists

By  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 5, 1999-05 ,pp. : 657-660

Informa Healthcare

Access to resources Recommend Favorite

Erratum: Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi H, Miyazawa S, Iwai T, Takezawa M, Saegusa M, Watanabe M and Koizumi W. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer. 2013;119:4094-102.

By  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1283-1285

Blackwell Publishing

Access to resources Recommend Favorite